Importantly, ICB has been found to be able to induce durable responses among multiple types of cancer both in patients and murine model.784 Two inhibitory molecules, the cytotoxic CTLA-4 and PD-1, have attracted much attention, because blockage of the CTLA-4 or PD-1 signaling has prominently improved the survival of patients with metastatic solid cancers.785 Furthermore, ICB alone or combinations with other immunotherapies, such as adoptive cell therapy and DC vaccination, has displayed some survival benefit for patients with advanced cancer.785. Here, CTLA4 is linked to cancer.